Cognition Therapeutics (CGTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CGTX Stock Price Chart Interactive Chart >
CGTX Price/Volume Stats
| Current price | $1.74 | 52-week high | $6.27 |
| Prev. close | $1.70 | 52-week low | $1.07 |
| Day low | $1.66 | Volume | 25,897 |
| Day high | $1.90 | Avg. volume | 76,685 |
| 50-day MA | $1.87 | Dividend yield | N/A |
| 200-day MA | $2.00 | Market Cap | 50.59M |
Cognition Therapeutics (CGTX) Company Bio
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Latest CGTX News From Around the Web
Below are the latest news stories about COGNITION THERAPEUTICS INC that investors may wish to consider to help them evaluate CGTX as an investment opportunity.
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 ResultsConference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the market |
Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 ResultsConference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the marke |
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMDNEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that its Investigational New Drug (IND) application for the investigation of CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) has been cleared by the U.S. Food and Drug Administration (FDA). Cognition plans to initiate the Phase 2 MAGNIFY trial of its oral drug candidate, CT1812 in 2023 in individuals with dry AMD who have measurable GA. “We enjoyed a c |
Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare ConferencePURCHASE, N.Y., March 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s president and CEO, Lisa Ricciardi will present at the annual Oppenheimer & Co Healthcare Conference taking place in a virtual format from March 13-15, 2023. Details of Cognition’s presentation are as follows: Event: Oppenheimer & Co Healthcare Conference Date/Time: Wednesday, March 15, 2023 at 10:00 a.m. ETWebcast: https://wsw.com/webca |
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s DiseaseNEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S. Food and Drug Administration comment period and may now proceed with the 540-patient Phase 2 START study of CT1812 in adults with mild cognitive impairment or early Alzheimer’s disease. This randomized placebo-controlled trial will be conducted at approximately 50-to-60 sites in North America including those premier institutions in the Alzheimer's Clinical Trials Consort |
CGTX Price Returns
| 1-mo | -3.33% |
| 3-mo | -21.62% |
| 6-mo | -0.57% |
| 1-year | -46.13% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -17.14% |
| 2022 | -66.77% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...